Interferon alpha treatment of patients with impaired interferon gamma signaling

Journal of Clinical Immunology

Volumn 33, Issue 5, 2013, Pages 991-1001

  Bax, H I ^a,b   Freeman, A F ^a   Ding, L ^a   Hsu, A P ^a   Marciano, B ^a   Kristosturyan, E ^a   Jancel, T ^c   Spalding, C ^a   Pechacek, J ^a   Olivier, K N ^a   Barnhart, L A ^a   Boris, L ^a   Frein, C ^a   Claypool, R J ^a   Anderson, V ^a   Zerbe, C S ^a   Holland, S M ^a   Sampaio, E P ^a  

^a Laboratory of Clinical Infectious Diseases   (United States)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

IFN ; IFN ; IFN receptor deficiency; mycobacterial disease; nontuberculous mycobacteria; STAT1

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; ANTIMYCOBACTERIAL AGENT; AZITHROMYCIN; CAPREOMYCIN; CLARITHROMYCIN; CLOFAZIMINE; COTRIMOXAZOLE; DOXYCYCLINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 1BETA; LEVOFLOXACIN; LINEZOLID; MEROPENEM; PEGINTERFERON ALPHA; RIFAMPICIN; TIGECYCLINE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; ATYPICAL MYCOBACTERIOSIS; CASE REPORT; CHILD; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EX VIVO STUDY; FEMALE; GENE EXPRESSION; GENE INDUCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERFERON GAMMA RECEPTOR DEFICIENCY; MALE; MYCOBACTERIUM INTRACELLULARE AVIUM; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN DEFICIENCY; SCHOOL CHILD; SIGNAL TRANSDUCTION;

ADULT; CELLS, CULTURED; CHILD, PRESCHOOL; CYTOKINES; FEMALE; GENE EXPRESSION; HUMANS; INTERFERON-ALPHA; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MYCOBACTERIUM; MYCOBACTERIUM INFECTIONS; RECEPTORS, INTERFERON; SIGNAL TRANSDUCTION; YOUNG ADULT;

EID: 84879232444     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-013-9882-5     Document Type: Article

References (43)

1. Boisson-Dupuis S, Kong XF, Okada S, Cypowyj S, Puel A, Abel L, et al. Inborn errors of human STAT1: allelic heterogeneity governs the diversity of immunological and infectious phenotypes. Curr Opin Immunol. 2012;24:364-78.
2. Holland SM. Immunotherapy of mycobacterial infections. Semin Respir Infect. 2001;16:47-59.
3. Stark GR, Darnell Jr JE. The JAK-STAT pathway at twenty. Immunity. 2012;36:503-14.
4. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004;25:677-86.
5. Heseler K, Spekker K, Schmidt SK, MacKenzie CR, Däubener W. Antimicrobial and immunoregulatory effects mediated by human lung cells: role of IFN-gamma-induced tryptophan degradation. FEMS Immunol Med Microbiol. 2008;52:273-81.
6. Fallarino F, Grohmann U, Puccetti P. Indoleamine 2,3-dioxygenase: from catalyst to signaling function. Eur J Immunol. 2012;42:1932-7.
7. Marciano BE, Wesley R, De Carlo ES, Anderson VL, Barnhart LA, Darnell D, et al. Long-term interferon-gamma therapy for patients with chronic granulomatous disease. Clin Infect Dis. 2004;39:692-9.
8. Key Jr LL, Rodriguez RM, Willi SM, Wright NM, Hatcher HC, Eyre DR, et al. Long-term treatment of osteopetrosis with recombinant human interferon gamma. N Engl J Med. 1995;332:1594-9.
9. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, et al. Peginterferon alpha-2b or alpha-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361:580-93. Erratum in: N Engl J Med. 2009;361:1027.
10. Senoh D, Hanaoka U, Tanaka Y, Tanaka H, Hayashi K, Yanagihara T, et al. Antenatal ultrasonographic features of fetal giant hemangiolymphangioma. Ultrasound Obstet Gynecol. 2001;17:252-4.
11. Simonsson B, Hjorth-Hansen H, Bjerrum OW, Porkka K. Interferon alpha for treatment of chronic myeloid leukemia. Curr Drug Targets. 2011;12:420-8.
12. Solovic I, Sester M, Gomez-Reino JJ, Rieder HL, Ehlers S, Milburn HJ, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J. 2010;36:1185-206.
13. Besada E. Rapid growing mycobacteria and TNF-α blockers: case report of a fatal lung infection with Mycobacterium abscessus in a patient treated with infliximab, and literature review. Clin Exp Rheumatol. 2011;29:705-7.
14. Winthrop KL, Chang E, Yamashita S, Iademarco MF, LoBue PA. Nontuberculous mycobacteria infections and anti-tumor necrosis factor-α therapy. Emerg Infect Dis. 2009;15:1556-61.
15. Lluch P, Urruticoechea A, Lluch J, Moll MC, Matos M, Benet JM, et al. Development of leprosy in a patient with rheumatoid arthritis during treatment with etanercept: a case report. Semin Arthritis Rheum. 2012;42:127-30.
16. Smith JA, Kauffman CA. Endemic fungal infections in patients receiving tumour necrosis factor-alpha inhibitor therapy. Drugs. 2009;69:1403-15.
17. Trinchieri G. Type I, interferon: friend or foe? J Exp Med. 2010;207:2053-63.
18. Novikov A, Cardone M, Thompson R, Shenderov K, Kirschman KD, Mayer-Barber KD, et al. Mycobacterium tuberculosis triggers host type I IFN signaling to regulate IL-1β production in human macrophages. J Immunol. 2011;187:2540-7.
19. Antonelli LR, Gigliotti Rothfuchs A, Goncalves R, Roffe E, Cheever AW, et al. Intranasal Poly-IC treatment exacerbates tuberculosis in mice through the pulmonary recruitment of a pathogen-permissive monocyte/macrophage population. J Clin Invest. 2010;120:1674-82.
20. Mayer-Barber KD, Andrade BB, Barber DL, Hieny S, Feng CG, Caspar P, et al. Innate and adaptive interferons suppress IL-1α and IL-1β production by distinct pulmonary myeloid subsets during Mycobacterium tuberculosis infection. Immunity. 2011;35:1023-34.
21. Holland SM, Dorman SE, Kwon A, Pitha-Rowe IF, Frucht DM, Gerstberger SM, et al. Abnormal regulation of interferon-gamma, interleukin-12, and tumor necrosis factor-alpha in human interferon-gamma receptor 1 deficiency. J Infect Dis. 1998;178:1095-104.
22. Sologuren I, Boisson-Dupuis S, Pestano J, Vincent QB, Fernández-Pérez L, Chapgier A, et al. Partial recessive IFN-γR1 deficiency: genetic, immunological and clinical features of 14 patients from 11 kindreds. Hum Mol Genet. 2011;20:1509-23.
23. Dorman SE, Picard C, Lammas D, Heyne K, van Dissel JT, Baretto R, et al. Clinical features of dominant and recessive interferon gamma receptor 1 deficiencies. Lancet. 2004;364:2113-21.
24. Martinez FO, Gordon S, Locati M, Mantovani A. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol. 2006;177:7303-11.
25. Lacey DC, Achuthan A, Fleetwood AJ, Dinh H, Roiniotis J, Scholz GM, et al. Defining GM-CSF- and macrophage-CSF-dependent macrophage responses by in vitro models. J Immunol. 2012;188:5752-65.
26. Tassiulas I, Hu X, Ho H, Kashyap Y, Paik P, Hu Y, et al. Amplification of IFN-alpha-induced STAT1 activation and inflammatory function by Syk and ITAM-containing adaptors. Nat Immunol. 2004;5:1181-9.
27. Hu X, Ivashkiv LB. Cross-regulation of signaling pathways by interferon-gamma: implications for immune responses and autoimmune diseases. Immunity. 2009;31:539-50.
28. Casanova JL, Holland SM, Notarangelo LD. Inborn errors of human JAKs and STATs. Immunity. 2012;36:515-28.
29. Aghemo A, Rumi MG, Colombo M. Pegylated IFN-alpha2a and ribavirin in the treatment of hepatitis C. Expert Rev Anti Infect Ther. 2009;7:925-35.
30. Keating GM. Peginterferon-alpha-2a (40 kD): a review of its use in chronic hepatitis B. Drugs. 2009;69:2633-60.
31. Dorman SE, Holland SM. Mutation in the signal-transducing chain of the interferon-gamma receptor and susceptibility to mycobacterial infection. J Clin Invest. 1998;101:2364-9.
32. Ward CM, Jyonouchi H, Kotenko SV, Smirnov SV, Patel R, Aguila H, et al. Adjunctive treatment of disseminated Mycobacterium avium complex infection with interferon alpha-2b in a patient with complete interferon-gamma receptor R1 deficiency. Eur J Pediatr. 2007;166:981-5.
33. Rapkiewicz AV, Patel SY, Holland SM, Kleiner DE. Hepatoportal venopathy due to disseminated Mycobacterium avium complex infection in a child with IFN-gamma receptor 2 deficiency. Virchows Arch. 2007;451:95-100.
34. Yarilina A, Ivashkiv LB. Type I interferon: a new player in TNF signaling. Curr Dir Autoimmun. 2010;11:94-104.
35. Manca C, Tsenova L, Bergtold A, Freeman S, Tovey M, Musser JM, et al. Virulence of a Mycobacterium tuberculosis clinical isolate in mice is determined by failure to induce Th1 type immunity and is associated with induction of IFN-alpha/beta. Proc Natl Acad Sci USA. 2001;98:5752-7.
36. Bouchonnet F, Boechat N, Bonay M, Hance AJ. Alpha/beta interferon impairs the ability of human macrophages to control growth of Mycobacterium bovis BCG. Infect Immun. 2002;70:3020-5.
37. Berry MP, Graham CM, McNab FW, Xu Z, Bloch SA, Oni T, et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature. 2010;466:973-7.
38. Ottenhoff TH, Dass RH, Yang N, Zhang MM, Wong HE, Sahiratmadja E, et al. Genome-wide expression profiling identifies type 1 interferon response pathways in active tuberculosis. PLoS One. 2012;7:e45839.
39. Kuchtey J, Fulton SA, Reba SM, Harding CV, Boom WH. Interferon-alpha/beta mediates partial control of early pulmonary Mycobacterium bovis bacillus Calmette-Guerin infection. Immunology. 2006;118:39-49.
40. Denis M. Recombinant murine beta interferon enhances resistance of mice to systemic Mycobacterium avium infection. Infect Immun. 1991;59:1857-9.
41. Lande R, Giacomini E, Grassi T, Remoli ME, Iona E, Miettinen M, et al. IFN-alpha/beta released by Mycobacterium tuberculosis-infected human dendritic cells induces the expression of CXCL10: selective recruitment of NK and activated T cells. J Immunol. 2003;170:1174-82.
42. van de Wetering D, van Wengen A, Savage NDL, van de Vosse E, van Dissel JT. IFN-α cannot substitute lack of IFN-γ responsiveness in cells of an IFN-γR1 deficient patient. Clin Immunol. 2011;138:282-90.
43. Bogunovic D, Byun M, Durfee LA, Abhyankar A, Sanal O, Mansouri D, et al. Mycobacterial disease and impaired IFN-γ immunity in humans with inherited ISG15 deficiency. Science. 2012;337:1684-8.